Amyloid precursor protein (APP) and its extracellular domain, soluble APP alpha (sAPPα) play important physiological and neuroprotective roles. However, rare forms of familial Alzheimer’s disease are associated with mutations in APP that increase toxic amyloidogenic cleavage of APP and produce amyloid beta (Aβ) at the expense of sAPPα and other non-amyloidogenic fragments. Although mitochondrial dysfunction has become an established hallmark of neurotoxicity, the link between Aβ and mitochondrial function is unclear. In this study we investigated the effects of increased levels of neuronal APP or Aβ on mitochondrial metabolism and gene expression, in human SH-SY5Y neuroblastoma cells. Increased non-amyloidogenic processing of APP, but not A...
Brains affected by Alzheimer’s disease (AD) show a large spectrum of mitochondrial alterations at bo...
Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) and increased productio...
This research is supported by Alzheimer's Research UK, the Wellcome Trust and the Biotechnology and ...
Amyloid precursor protein (APP) and its extracellular domain, soluble APP alpha (sAPPα) play importa...
Despite clear evidence of a neuroprotective physiological role of amyloid precursor protein (APP) an...
Evidence suggests that amyloid-beta (Aβ) protein is a key factor in the pathogenesis of Alzheimer's ...
Background:Dominant missense mutations in the amyloid-β protein precursor (AβPP) cause early-onset f...
Background:Dominant missense mutations in the amyloid-β protein precursor (AβPP) cause early-onset f...
<div><p>One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), whic...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
This is the published version. Copyright 2011 by Journal of Alzheimer's Disease.Accumulation of amyl...
This is the published version. Copyright 2011 by Journal of Alzheimer's Disease.Accumulation of amyl...
Brains affected by Alzheimer’s disease (AD) show a large spectrum of mitochondrial alterations at bo...
Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) and increased productio...
This research is supported by Alzheimer's Research UK, the Wellcome Trust and the Biotechnology and ...
Amyloid precursor protein (APP) and its extracellular domain, soluble APP alpha (sAPPα) play importa...
Despite clear evidence of a neuroprotective physiological role of amyloid precursor protein (APP) an...
Evidence suggests that amyloid-beta (Aβ) protein is a key factor in the pathogenesis of Alzheimer's ...
Background:Dominant missense mutations in the amyloid-β protein precursor (AβPP) cause early-onset f...
Background:Dominant missense mutations in the amyloid-β protein precursor (AβPP) cause early-onset f...
<div><p>One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), whic...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
One hallmark of Alzheimer´s disease are senile plaques consisting of amyloid beta (Aβ), which derive...
This is the published version. Copyright 2011 by Journal of Alzheimer's Disease.Accumulation of amyl...
This is the published version. Copyright 2011 by Journal of Alzheimer's Disease.Accumulation of amyl...
Brains affected by Alzheimer’s disease (AD) show a large spectrum of mitochondrial alterations at bo...
Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) and increased productio...
This research is supported by Alzheimer's Research UK, the Wellcome Trust and the Biotechnology and ...